151 related articles for article (PubMed ID: 20151048)
41. Concurrent chemoradiotherapy for locally advanced esophageal cancer--a pilot study by using daily low-dose cisplatin and continuous infusion of 5-fluorouracil.
Hsu CH; Yeh KH; Lui LT; Lee YC; Bu CF; Wang HP; Lin JT; Cheng AL
Anticancer Res; 1999; 19(5C):4463-7. PubMed ID: 10650793
[TBL] [Abstract][Full Text] [Related]
42. Phase II trial of neoadjuvant cisplatin, 5-fluorouracil and interferon-alpha in operable squamous cell carcinoma of the esophagus.
Bazarbashi S; Abdelsalam M; Amin T; El-Bassiouni M; Soudy H; Elweshi A; Alhusseiny H; Rehman K; Memon M; Ajarim D
Chemotherapy; 2008; 54(4):315-22. PubMed ID: 18701820
[TBL] [Abstract][Full Text] [Related]
43. Phase I trial of combined chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for patients with locally advanced squamous cell carcinoma of the head and neck.
Tsukuda M; Mikami Y; Tanigaki Y; Katori H; Horiuchi C; Ikeda Y; Taguchi T; Ono M; Yoshida T; Sakuma Y; Aikoh K
Int J Clin Oncol; 2004 Jun; 9(3):161-6. PubMed ID: 15221599
[TBL] [Abstract][Full Text] [Related]
44. Phase I trial of concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Katori H; Tsukuda M; Mochimatu I; Ishitoya J; Kawai S; Mikami Y; Matsuda H; Tanigaki Y; Horiuchi C; Ikeda Y; Taguchi T; Ono M; Yoshida T; Hirose S; Sakuma Y; Yamamoto K
Br J Cancer; 2004 Jan; 90(2):348-52. PubMed ID: 14735175
[TBL] [Abstract][Full Text] [Related]
45. Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey.
Schneider M; Etienne MC; Milano G; Thyss A; Otto J; Dassonville O; Mobayen H; Saudes L; Guillot T; Demard F
J Clin Oncol; 1995 Jul; 13(7):1656-62. PubMed ID: 7602355
[TBL] [Abstract][Full Text] [Related]
46. Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Kato K; Nakajima TE; Ito Y; Katada C; Ishiyama H; Tokunaga SY; Tanaka M; Hironaka S; Hashimoto T; Ura T; Kodaira T; Yoshimura K
Jpn J Clin Oncol; 2013 Jun; 43(6):608-15. PubMed ID: 23585687
[TBL] [Abstract][Full Text] [Related]
47. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie.
Lorenzen S; Schuster T; Porschen R; Al-Batran SE; Hofheinz R; Thuss-Patience P; Moehler M; Grabowski P; Arnold D; Greten T; Müller L; Röthling N; Peschel C; Langer R; Lordick F
Ann Oncol; 2009 Oct; 20(10):1667-73. PubMed ID: 19549707
[TBL] [Abstract][Full Text] [Related]
48. [Comparison between docetaxel plus cisplatin and cisplatin plus fluorouracil in the neoadjuvant chemoradiotherapy for local advanced esophageal squamous cell carcinoma].
Wu S; Chen MY; Luo JC; Wei L; Chen Z
Zhonghua Zhong Liu Za Zhi; 2012 Nov; 34(11):873-6. PubMed ID: 23291141
[TBL] [Abstract][Full Text] [Related]
49. Association between radiation dose and pathological complete response after preoperative radiochemotherapy in esophageal squamous cell cancer.
Ordu AD; Nieder C; Geinitz H; Scherer V; Kup PG; Schuster T; Combs SE; Fakhrian K
Anticancer Res; 2014 Dec; 34(12):7255-61. PubMed ID: 25503157
[TBL] [Abstract][Full Text] [Related]
50. Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus.
Heath EI; Burtness BA; Heitmiller RF; Salem R; Kleinberg L; Knisely JP; Yang SC; Talamini MA; Kaufman HS; Canto MI; Topazian M; Wu TT; Olukayode K; Forastiere AA
J Clin Oncol; 2000 Feb; 18(4):868-76. PubMed ID: 10673530
[TBL] [Abstract][Full Text] [Related]
51. Long-term administration of low-dose cisplatin plus 5-fluorouracil prolongs the postoperative survival of patients with esophageal cancer.
Shiozaki A; Yamagishi H; Itoi H; Fujiwara H; Kikuchi S; Okamoto K; Ichikawa D; Fuji N; Ochiai T; Sonoyama T; Ueda Y
Oncol Rep; 2005 Apr; 13(4):667-72. PubMed ID: 15756440
[TBL] [Abstract][Full Text] [Related]
52. Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer.
Khushalani NI; Leichman CG; Proulx G; Nava H; Bodnar L; Klippenstein D; Litwin A; Smith J; Nava E; Pendyala L; Smith P; Greco W; Berdzik J; Douglass H; Leichman L
J Clin Oncol; 2002 Jun; 20(12):2844-50. PubMed ID: 12065561
[TBL] [Abstract][Full Text] [Related]
53. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
Satake H; Tahara M; Mochizuki S; Kato K; Hara H; Yokota T; Kiyota N; Kii T; Chin K; Zenda S; Kojima T; Bando H; Yamazaki T; Iwasa S; Honma Y; Hamauchi S; Tsushima T; Ohtsu A
Cancer Chemother Pharmacol; 2016 Jul; 78(1):91-9. PubMed ID: 27193097
[TBL] [Abstract][Full Text] [Related]
54. Neoadjuvant chemotherapy in squamous cell carcinoma of the esophagus using low dose continuous infusion 5-fluorouracil and cisplatin: results of a prospective study.
Aroori S; Parshad R; Kapoor A; Gupta SD; Kumar A; Chattophadyay TK
Indian J Cancer; 2004; 41(1):3-7. PubMed ID: 15105572
[TBL] [Abstract][Full Text] [Related]
55. Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.
Hu G; Wang Z; Wang Y; Zhang Q; Tang N; Guo J; Liu L; Han X
Drug Des Devel Ther; 2016; 10():2129-36. PubMed ID: 27445460
[TBL] [Abstract][Full Text] [Related]
56. Phase I Dose-Escalation Study of Docetaxel, Cisplatin, and 5-Fluorouracil Combination Chemotherapy in Patients With Advanced Esophageal Carcinoma.
Satomura H; Nakajima M; Sasaki K; Yamaguchi S; Domeki Y; Takahashi M; Muroi H; Kubo T; Kikuchi M; Otomo H; Ihara K; Kato H
Int Surg; 2015 Jun; 100(6):1153-8. PubMed ID: 26414837
[TBL] [Abstract][Full Text] [Related]
57. Doxorubicin, cisplatin, and fluorouracil combination therapy for metastatic esophageal squamous cell carcinoma.
Honda M; Miura A; Izumi Y; Kato T; Ryotokuji T; Monma K; Fujiwara J; Egashira H; Nemoto T
Dis Esophagus; 2010 Nov; 23(8):641-5. PubMed ID: 20545978
[TBL] [Abstract][Full Text] [Related]
58. A phase I study of cabazitaxel in combination with platinum and 5-fluorouracil (PF) in locally advanced squamous cell carcinoma of head and neck (LA-SCCHN).
Camille N; Rozehnal J; Roy E; Uczkowski D; Olson A; Genden E; Teng M; Bakst R; Gupta V; Posner M; Misiukiewicz K
Oral Oncol; 2017 Aug; 71():99-104. PubMed ID: 28688700
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of combined docetaxel and nedaplatin chemotherapy for recurrent esophageal cancer compared with conventional chemotherapy using cisplatin and 5-fluorouracil: a retrospective study.
Fujita Y; Hiramatsu M; Kawai M; Sumiyoshi K; Nishimura H; Tanigawa N
Dis Esophagus; 2008; 21(6):496-501. PubMed ID: 18840134
[TBL] [Abstract][Full Text] [Related]
60. Taxane, platinum and 5-FU prior to chemoradiotherapy benefits patients with stage IV neck node-positive head and neck cancer and a good performance status.
Lowe NM; Bernstein JM; Mais K; Garcez K; Lee LW; Sykes A; Thomson DJ; Homer JJ; West CM; Slevin NJ
J Cancer Res Clin Oncol; 2018 Feb; 144(2):389-401. PubMed ID: 29222650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
